CIK 0001674416
- Large accelerated filer
CRISPR Therapeutics AG
Sign in to watch- Ticker
- CRSP
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- Switzerland
- Entity type
- Operating
- EIN
- 473173478
- Phone
- +1 617-315-4600
- Business address
- BAARERSTRASSE 14, ZUG, Switzerland
- Former names
- CRISPR Therapeutics AG
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $4,881,673
- in 7 filings, $1.5M under 10b5-1 plans
Net −$4,881,673. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2017-04-26 | Kulkarni Samarth Chief Business Officer | Sale | −3,275 | $16.74 | $55K | 134,047 |
| 2017-04-26 | Kulkarni Samarth Chief Business Officer | Exercise or conversion · Stock Options (Right to Buy) | −3,275 | 296,764 | ||
| 2017-04-26 | Dylan-Hyde Tyler Chief Legal Officer | Sale | −3,200 | $16.76 | $54K | 180,495 |
| 2017-04-25 | Dylan-Hyde Tyler Chief Legal Officer | Sale | −4,800 | $16.87 | $81K | 183,695 |
| 2017-04-25 | Kulkarni Samarth Chief Business Officer | Exercise or conversion | +5,115 | $1.81 | $9K | 139,162 |
| 2017-04-25 | Kulkarni Samarth Chief Business Officer | Sale | −5,115 | $16.87 | $86K | 134,047 |
| 2017-04-25 | Kulkarni Samarth Chief Business Officer | Exercise or conversion · Stock Options (Right to Buy) | −5,115 | 300,039 | ||
| 2017-04-24 | Dylan-Hyde Tyler Chief Legal Officer | Sale | −3,522 | $16.44 | $58K | 188,495 |
| 2017-04-24 | Kulkarni Samarth Chief Business Officer | Exercise or conversion | +3,500 | $1.81 | $6K | 137,547 |
| 2017-04-24 | Kulkarni Samarth Chief Business Officer | Sale | −3,500 | $16.46 | $58K | 134,047 |
| 2017-04-24 | Kulkarni Samarth Chief Business Officer | Exercise or conversion · Stock Options (Right to Buy) | −3,500 | 305,154 | ||
| 2017-04-21 | Dylan-Hyde Tyler Chief Legal Officer | Sale | −3,010 | $17.02 | $51K | 192,017 |
| 2017-04-21 | Kulkarni Samarth Chief Business Officer | Exercise or conversion | +3,000 | $1.81 | $5K | 137,047 |
| 2017-04-21 | Kulkarni Samarth Chief Business Officer | Sale | −3,000 | $17.01 | $51K | 134,047 |
| 2017-04-21 | Kulkarni Samarth Chief Business Officer | Exercise or conversion · Stock Options (Right to Buy) | −3,000 | 308,654 | ||
| 2017-04-20 | Novak Rodger Chief Executive Officer | Exercise or conversion | +2,294 | $1.81 | $4K | 1,217,299 |
| 2017-04-20 | Novak Rodger Chief Executive Officer | Sale | −2,294 | $17.37 | $40K | 1,215,005 |
| 2017-04-20 | Novak Rodger Chief Executive Officer | Exercise or conversion · Stock Options (Right to Buy) | −2,294 | 218,093 | ||
| 2017-04-20 | Kulkarni Samarth Chief Business Officer | Exercise or conversion | +2,800 | $1.81 | $5K | 136,847 |
| 2017-04-20 | Kulkarni Samarth Chief Business Officer | Sale | −2,800 | $17.36 | $49K | 134,047 |
Page 66 of 74 · 1,471 trades